{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"3.3","upperLimit":"14.3","value":"5.9"},{"groupId":"OG001","lowerLimit":"3.8","upperLimit":"24.3","value":"6.9"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"47"},{"groupId":"OG001","value":"13"}],"units":"Participants"}],"description":"The Kaplan-Meier method will be used to estimate the median OS time and its 95% CI.","dispersionType":"95% Confidence Interval","groups":[{"description":"Patients receive ruxolitinib phosphate PO BID on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.\n\nLaboratory Biomarker Analysis: Correlative studies\n\nRuxolitinib Phosphate: Given PO","id":"OG000","title":"Diffuse Large B-cell Lymphoma (DLBCL)"},{"description":"Patients receive ruxolitinib phosphate PO BID on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.\n\nLaboratory Biomarker Analysis: Correlative studies\n\nRuxolitinib Phosphate: Given PO","id":"OG001","title":"Peripheral T-cell Non-Hodgkin Lymphoma (PTCL)"}],"paramType":"MEDIAN","reportingStatus":"POSTED","timeFrame":"From the date of start of treatment to date of death due to any cause, assessed up to 60 months","title":"Overall Survival (OS)","type":"SECONDARY","unitOfMeasure":"Months"}